Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189798 · ClinicalTrials.gov registry record · NA
Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness
A NA study, sponsored by Advanced Bionics.
- Terminated
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT02189798: Clinical Trial NA study, sponsored by Advanced Bionics.
NCT02189798 is a NA study that was terminated before completion, run by Advanced Bionics. The registered enrollment target is 67 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02189798, a NA study, was terminated before completion, sponsored by Advanced Bionics.
- TERMINATED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this feasibility study is to evaluate whether low-frequency acoustic hearing sensitivity can be preserved in newly implanted adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) using the HiResolution™ 90K™ Advantage cochlear implant with the HiFocus™ Mid-Scala electrode to support the development of electro-acoustic stimulation technology (EAS).
Primary Outcome
Unaided pure tone hearing threshold measurement in the implanted ear at months 3, 6 and 12 months after surgery compared to pre-implant audiometric thresholds (using pure-tone average of 125 - 1000 Hz for comparison)
Interventions
- DEVICE HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode
- DEVICE EAS sound processor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2014-10-21 |
| Est. Completion | 2022-03-29 |
| Phase | NA |
Why NCT02189798 stopped before completion
NCT02189798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode is the first listed.
NCT02189798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02189798 about?
NCT02189798 is a clinical study titled "Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness". The purpose of this feasibility study is to evaluate whether low-frequency acoustic hearing sensitivity can be preserved in newly implanted adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) using the ...
What is the current status of trial NCT02189798?
This trial is currently terminated. It is a NA study. The enrollment target is 67 participants. The study started on 2014-10-21. Estimated completion is 2022-03-29.
What interventions are being tested in trial NCT02189798?
The interventions under investigation include: HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode (DEVICE), EAS sound processor (DEVICE).
Who is sponsoring clinical trial NCT02189798?
This trial is sponsored by Advanced Bionics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02189798's enrollment target sits among peer trials
67 1139th of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI